Astex and Genentech Enter $490M+ Collaboration to Target Cell-Cycle Regulator in Breast Cancer
核心洞察
Astex Pharmaceuticals (搜索) and Genentech have entered an exclusive worldwide research collaboration and license agreement to develop small molecule drug candidates for breast cancer (搜索).
The deal leverages Astex's fragment-based drug discovery platform to target a key cell-cycle-dependent regulator (搜索), with Genentech assuming responsibility for preclinical and clinical development as well as global commercialization.
Astex will receive a $25 million upfront payment and is eligible for milestone payments potentially exceeding $490 million, plus tiered royalties on net sales.
Astex Pharmaceuticals (搜索) and Genentech, a member of the Roche Group, announced today an exclusive, worldwide research collaboration and license agreement aimed at identifying small molecule drug candidates with selective inhibitory activity as potential treatments for breast cancer (搜索). The collaboration, announced from Cambridge, UK, on July 6, 2026, brings together Astex's industry-leading fragment-based drug discovery platform and Genentech's deep expertise in oncology development and commercialization.
Under the terms of the agreement, Astex will grant Genentech an exclusive license to compounds from Astex's existing drug discovery program for breast cancer (搜索). The two companies will collaborate to accelerate the further optimization and development of lead compounds toward the identification of preclinical candidates. Genentech will assume sole responsibility for preclinical and clinical development of lead candidates, as well as the global commercialization of all medicines arising from the collaboration.
Financial Terms and Milestone Structure
The financial framework of the deal includes a $25 million upfront payment to Astex. The company is also eligible to receive additional payments upon the achievement of preclinical, clinical, regulatory, and sales milestones, potentially totaling more than $490 million. Beyond milestone payments, Astex will receive tiered royalties on net sales of any medicines that emerge from the collaboration.
Scientific Foundation and Target Rationale
Astex's drug discovery program originated from an earlier collaborative project conducted under the company's strategic alliance agreement with Newcastle University and Cancer Research Horizons (搜索). The program focuses on a key cell-cycle-dependent regulator (搜索) implicated in breast cancer (搜索), an area that both companies describe as having significant unmet medical need.
Michelle Jones, president of Astex Pharmaceuticals (搜索), emphasized the scientific innovation underpinning the collaboration: "Working together with colleagues from Newcastle University, Astex's fragment-based drug discovery expertise has led to the discovery of a novel and innovative approach to selectively inhibit this key oncology target for breast cancer (搜索) therapy."
Jones further highlighted the strategic fit between the two organizations, noting Genentech's "focus on embracing innovation, its expertise in oncology and its longstanding dedication to innovation for breast cancer (搜索) patients."
Industry Context and Unmet Need
Boris L. Zaïtra, Head of Roche Corporate Business Development, underscored Roche's commitment to advancing precision oncology: "We are committed to pushing the boundaries of scientific innovation and turning breakthroughs into better outcomes for people with breast cancer (搜索)." Zaïtra added that the collaboration reflects a strategy of "working alongside partners like Astex Pharmaceuticals (搜索) in pursuit of precision therapies against cell-cycle regulators" and "following the science to focus our innovation on the areas of the highest unmet need."
The partnership represents a convergence of Astex's fragment-based drug discovery capabilities—a methodology that has established the company as a leader in identifying novel small molecule therapeutics—with Genentech's extensive oncology development infrastructure and commercial reach as part of the Roche Group. Astex, a wholly owned subsidiary of Otsuka Pharmaceutical (搜索) Co. Ltd., maintains a proprietary pipeline of novel therapies alongside multiple partnered programs with leading pharmaceutical companies.